In a pan-cancer analysis of patients using PD-1 inhibitors, aspirin use was shown to be associated with a higher risk of irAEs (OR 1.20, 95% CI 1.09–1.31, FDR adjusted p = 0.002) (Figure 4). This evidence concerns the gene PDCD1 and cancer.